Figure 1




280-03-08
280-21-09
280-29-12
280-31-01
280-34-02
Lintuzumab
% CD33 surface expression
100
80
60
40
20
0
time [h]
0
5
10
15
20
25

Figure 2


280-50-01
280-61-07
283-03-03
283-05-01
lintuzumab
% CD33 surface expression
100
80
60
40
20
0
0
5
10
15
20
25
time (h)

3/5

Figure 3



283-07-03
280-50-01(mut)
283-11-03
283-14-01
280-31-01(mut)
Lintuzumab
% CD33 surface expression
100
80
60
40
20
0
0
5
10
15
20
25
time [h]

Figure 4




280-31-01(mut)
280-50-01(mut)
lintuzumab
% CD33 surface expression
100
80
60
40
20
0
0
5
10
15
20
25
time (h)

Figure 5


280-31-01(mut)
280-50-01(mut)
lintuzumab
relative cytotoxicity (%
100
80
60
40
20
0
0
5
10
15
20
25
time (h)